Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

サイズ 価格(税別)  
JPY 20932.00
JPY 16102.00
JPY 51460.00
JPY 78020.00

カスタマーフィードバック(5)

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MlXlSpVv[3Srb36gRZN{[Xl? MorINlAh|ryP MnzyNlQhcA>? Mm\ObY5pcWKrdIOg[ZhxemW|c3nvckBw\iCLRF:= NYi2[pV6OjV7NEC3NVI>
MV-4-11 NG\tdVNCeG:ydH;zbZMhSXO|YYm= NWDWcldIOi53IN88US=> M3yxflQ5KGh? MnPBbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MUOyOVEyOTV6Mx?=
THP-1 M{nvSGFxd3C2b4Ppd{BCe3OjeR?= NX25ZYVyOi53IN88US=> NH24NWQ1QCCq MWfpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NGO2N5EzPTFzMUW4Ny=>
MOLM 13 MljNRZBweHSxc3nzJGF{e2G7 NWXnZ2FZOi53IN88US=> MnfWOFghcA>? NV[4NpB{cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M4PYflI2OTFzNUiz
KBM3/Bu2506 Mo\zRZBweHSxc3nzJGF{e2G7 Mm\DNk42KM7:TR?= NIXHfWg1QCCq MULpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NX2zRlZvOjVzMUG1PFM>
Nalm-6 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\x[ZhKSzVyPUG4JO69VQ>? MkHONlUxPjFzMEG=
Reh MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XQWGlEPTB;M{Cg{txO NGDBXZkzPTB4MUGwNS=>
U2937 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF4IN88US=> M4DtT|I2ODZzMUCx
Mec-1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|Ux97zgNUCwJO69VQ>? NWP5XFZtOjVyNkGxNFE>
RPMI-8226 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD13MECg{txO MVuyOVA3OTFyMR?=
Molt-4 NYOxfGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLzTWM2OD1zOECg{txO MWeyOVA3OTFyMR?=
Nalm-6-FluR MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLyTWM2OD1{NUCg{txO MljJNlUxPjFzMEG=
Raji  M2fSdWZ2dmO2aX;uJGF{e2G7 MYKzxsDPxE1? Ml\XNlQwPDhxN{KgbC=> MYHpcoR2[2W|IHHjZ5VufWyjdHnvcpMhd2ZicEWzMEBxPjNiYX7kJJA4O8Li MWKyOFk1ODZ7NR?=
PBMC NFWxPGNHfW6ldHnvckBCe3OjeR?= NWTiRVdSPTBxMUCwJO69VQ>? MWOyOEBp NHXQVY9FVVOR NUjnfWxMcW6qaXLpeJMhW1SDVEGgdIhwe3Cqb4L5cIF1cW:w Mlz2NlQ6OTF6N{K=
MDA-231 NF\NS4tHfW6ldHnvckBCe3OjeR?= NYO2TVlQOTByIN88US=> NIK4VmQzPCCq MkXJSG1UVw>? NWjVSlNi\GWlcnXhd4V{KEmGTzDlfJBz\XO|aX;u NWLGeW1EOjR7MUG4O|I>
624.38mel  NI\qS|hHfW6ldHnvckBCe3OjeR?= NHG2SXQ2OCEQvF2= MVOyOEBp MWHEUXNQ MkPL[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w MnTBNlQ6OTF6N{K=
MDA-231 M{G4emZ2dmO2aX;uJGF{e2G7 MWK1NE0zODBizszN NV;3T495OjRiaB?= NFnLRZhFVVOR NXPnToFqcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= NV;xSVlvOjR7MUG4O|I>
624.38mel  NUjue3k4TnWwY4Tpc44hSXO|YYm= MUK1NE0zODBizszN NGjOdoEzPCCq NGTVc3NFVVOR NEXnN3pqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= MlXvNlQ6OTF6N{K=
HMECs MnfrSpVv[3Srb36gRZN{[Xl? NFfzNYoyODEEoN88UeKh NHrKeWk{PsLiaB?= NVTnSnFTcW6qaXLpeJMhUU[QzsRCpIFv\CCOUGOgbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnSSlEh\XiycnXzd4lwdg>? MnruNlQzOTF|Mke=
HMECs  MoHkSpVv[3Srb36gRZN{[Xl? M3\CblExOMLizszNxsA> M{joN|M3yqCq MoP2bY5pcWKrdIOgTWZP|rIEoH3l[IlifGWmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSCjbnSgV3RCXDNuIHL1eEBvd3Rib3[gV3RCXDJ? NXXMN41OOjR{MUGzNlc>
BJAB MlPIRZBweHSxc3nzJGF{e2G7 MnfPOeKh|ryP NUj6c|QxOjRiaB?= MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1\DO|I1ODV5MUS3
I-83 M1PnbGFxd3C2b4Ppd{BCe3OjeR?= M4LyVVXDqM7:TR?= MW[yOEBp NGTsbJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkLyNlQxPTdzNEe=
NALM6 MWfBdI9xfG:|aYOgRZN{[Xl? NWrueXh4PcLizszN NFvHPY8zPCCq NXfmO4VKcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MV:yOFA2PzF2Nx?=
DU-145 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWwMVExKM7:Zz;tcC=> M3uz[FQ5KGkEoB?= MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NE\3WmEzOzd|NEixOS=>
Nalm-6 M2roOmZ2dmO2aX;uJGF{e2G7 MXixNOKh|ryP MYexM|IwPCCq MkjzbY5lfWOnczDheZRweGijZ4m= MYmyN|Y5OTJ{Mx?=
Reh NH;iXZpHfW6ldHnvckBCe3OjeR?= NYDLUWhNOTEEoN88US=> MYixM|IwPCCq M{nNUIlv\HWlZYOgZZV1d3CqYXf5 NULGXFJEOjN4OEGyNlM>
Nalm-6 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLLNWlWUUN3MDFijNwyOOLCid88US=> M1nNSVI{PjhzMkKz
Reh NHe3UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxKOLKvEGw5qCK|ryP MlvQNlM3QDF{MkO=
HEC1A NEjic5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljQNVAxNTVyMDFOwG0> NWH3U|NQOjRiaB?= MnTVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGD0NYozOzV7NU[5Oy=>
AN3CA M2eybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxNFAuPTByIN88US=> NXvLTnBpOjRiaB?= MnvnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVH6W|RYOjN3OUW2PVc>
HEC50B NGrPe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\LTVExOC13MECg{txO MoDqNlQhcA>? MWTpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> MkHSNlM2QTV4OUe=
HEC1A MWrBdI9xfG:|aYOgRZN{[Xl? MmLONlAwOTByIN88US=> M4PvSFI1KGh? MYrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYrab5dHOjN3OUW2PVc>
AN3CA MWfBdI9xfG:|aYOgRZN{[Xl? MlHYNlAwOTByIN88US=> NFrsW4gzPCCq NYXPW3YxcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnjsNlM2QTV4OUe=
HEC50B M120VGFxd3C2b4Ppd{BCe3OjeR?= NXO5UJA1OjBxMUCwJO69VQ>? NVHUfHhbOjRiaB?= M1Pxcolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MXiyN|U6PTZ7Nx?=
EHEB MlK5RZBweHSxc3nzJGF{e2G7 MXu0NEDPxE1? NWPxT|hQOjRiaB?= M2HFT4lv\HWlZYOgZZBweHSxc3nz M1\5O|I{PDl5MEe1
A549 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v3SWlEPTB;MUWuO:KyOi56INM1US=> NGjBWVQzOzN5N{G5Ni=>
A549 GAPDH-deficient NHjs[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L4XmlEPTB;MUiuOeKyOi5|INM1US=> NWDmPI5GOjN|N{exPVI>
CLL  NWmxOHVpSXCxcITvd4l{KEG|c3H5 NGrGWYEyOCEQvF5CpC=> M4[yVlI1NTl4IHi= M2nr[olv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NIH6cpkzOjJyN{[4Oi=>
MEC1 MnnDRZBweHSxc3nzJGF{e2G7 Mn;sNVAxyqEQvF2= NXr1VXRCPzJiaB?= MXTpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MmrFNlIyOzJ7N{O=
U937  M2HHXGFxd3C2b4Ppd{BCe3OjeR?= NFHqZWExNjhizszN MlT0OE01QCCq M3X4R4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MViyNlA4PDdyMB?=
U937  M{f6OGFxd3C2b4Ppd{BCe3OjeR?= M4LWN|Eh|ryP MYq5OkBp MYrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NUK1bJRLOjJyMkO1NlM>
Daudi MVLBdI9xfG:|aYOgRZN{[Xl? MYeyNEDPxE1? NVLVTFBVQTZiaB?= NWqxOmRHcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NIjmRmIzOjB{M{WyNy=>
J45.01 NFz6WIpCeG:ydH;zbZMhSXO|YYm= MV:xJO69VQ>? M2fnelk3KGh? MluzbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MWiyNlAzOzV{Mx?=
RPMI 8226 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ3LkpCpOKyyqB|Lkeg{txO NUWwTGpvOjF7NEiyOlQ>
CEM MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLUTWM2OD1{LkVCpOKyyqByLkSg{txO NWi3VpdwOjF7NEiyOlQ>
Raji NXTVO2NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTiTWM2OD1yLkS3xsDDucLiMD6wOEDPxE1? MYiyNVk1QDJ4NB?=
U937 NUnuZ3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXjZohKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= M3H1Z|IyQTR6Mk[0
K562 M2fkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjKVlVbUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= NUi5UJBlOjF7NEiyOlQ>
NALM-6 M3;XR2Fxd3C2b4Ppd{BCe3OjeR?= Mk\4NVAh|ryPwrC= NIj0XJMzPCCq M4rZcolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NV;6WIRiOjF4OUmzPFM>
JMV-3 NVjyXIhDSXCxcITvd4l{KEG|c3H5 MmfMNVAh|ryPwrC= M3i0OFI1KGh? M2nYe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NF;JelAzOTZ7OUO4Ny=>
EHEB MV;GeY5kfGmxbjDBd5NigQ>? MXK1MVUxKM7:TR?= M322dFI1KGh? MYjk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NFjzbXczOTF4OEO5NS=>
JVM-2  MUTGeY5kfGmxbjDBd5NigQ>? NVexfWZwOzBizszN NYPPZVRQOjRiaB?= NIjNXW1l\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36= M1n0cFIyOTZ6M{mx
KBM3/Bu2506 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjWWoNKSzJyPUCuOlchyrWP NV\SZ3lXOjB7M{O1NFk>
KBM3/Bu2506 M4HQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMlYh|ryP M3PuU|I1KGh? M2\4UYlv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm Moj0NlA6OzN3MEm=
MDA-MB-231 NXzl[3g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwMDFOwG0> M4jxOlIxPDR5M{mw
MCF-7 NIDYUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG0NYhkUUN3ME2xOU4xKM7:TR?= MWmyNFQ1PzN7MB?=
HLE-B3  MnHNSpVv[3Srb36gRZN{[Xl? MVSyOUDPxE1? MV:0PEBp M2D0TYJtd2OtczDJSm4u|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44> NVHVTFNMOjB2M{WxOVg>
K562 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3VO|IhcA>? M4DsZWlEPTB;Mz6zJI5O MUOyNFMxPzF7OB?=
BW-225 NGrLWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|IxRTFwM{egx7cyOOLKkklCpO69VcLi NGP5b2IyQDZ4MUO4NC=>
OH-65 NILWNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LPVmlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= M1zNfFE5PjZzM{iw
GR-145 M2D3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvaO3FKSzJyPUKuO|Qhy5diMUFijLI5KCEQvF5CpC=> NGDaV2syQDZ4MUO4NC=>
A549 NWfYNW03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLlTplKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg MWOxPFY3OTN6MB?=
CaSki  MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnVemFKSzJyPUGuN|chy5diMUFijLI4KM7:TdMg MXyxPFY3OTN6MB?=
ZMK-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|IxRTFwM{egx7chOTEkiKK2JO69VcLi M334XFE5PjZzM{iw
SKW6.4 NH\mUlhCeG:ydH;zbZMhSXO|YYm= NWHrcnlqOC5yMT2xNEDPxE1? NUO5SHRkOjRxNEigbC=> MoiybY5lfWOnczDj[YxtKGSnYYToJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NVOzd485OThyOUKzOFA>
RPMI 8226 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XUXVI1KGh? MmjLTWM2OD1zLkW0xsDPxE1? NHPxUXoyPzl5NkG4Oi=>
MM.1S NFfC[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC0PEBp MYHJR|UxRTF|LkS4xsDPxE1? NF7VboUyPzl5NkG4Oi=>
MM.1R NFTrVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u2UFQ5KGh? M{L1OGlEPTB;M{OuO|kh|ryP MlrtNVc6PzZzOE[=
U937 NGHKZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNuMkCwJOKyKDV4MDDuUS=> NY[3NY03OTV7M{CzOlE>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% propylene glycol, 5% Tween 80, 65% D5W
混合させたのち直ちに使用することを推奨します。
30 mg/mL (suspension)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
in solvent
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01503242 Active not recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9 2012 Phase 1
NCT03159702 Recruiting Hematological Malignancy Undergoing a Related Donor Haploidentical HCT|Leukemia|Multiple Myeloma|Lymphoma Medical College of Wisconsin December 8 2017 Phase 2
NCT03333486 Recruiting Accelerated Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome Roswell Park Cancer Institute|National Cancer Institute (NCI) December 7 2017 Phase 2
NCT00448201 Completed Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) January 7 2011 Phase 2
NCT00474747 Completed Aplastic Anemia M.D. Anderson Cancer Center|National Heart Lung and Blood Institute (NHLBI)|National Cancer Institute (NCI) February 7 2006 Phase 1|Phase 2
NCT03494569 Recruiting Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|Minimal Residual Disease|Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) July 6 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STATシグナル伝達経路

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID